MMJ-001 / MMJ International - LARVOL DELTA

DEA clears way for MMJ to Import cannabis compounds for trials in Huntington’s Disease and MS (Huntington’s Disease News) - "The U.S. Drug Enforcement Administration (DEA) cleared MMJ to import the compounds from Canada, after the company made the request three months ago....MMJ-001 and MMJ-002 are two of MMJ’s lead therapeutic candidates, and are liquid formulations of highly purified THC and CBD. The company is developing MMJ-001 to treat spasticity (abnormal muscle tightness) in MS, and MMJ-002 to treat Huntington’s-associated chorea — a neurological condition marked by involuntary spasms or writhing movements."

Commercial

MMJ BioPharma cultivation in line for DEA license to grow cannabis (Yahoo Finance) - “MMJ BioPharma Cultivation…today announced that it has signed a memorandum of understanding (MOU) with MMJ International Holdings to grow cannabis and supply active pharmaceutical ingredients (API) for its drug product MMJ-001 and MMJ-002. MMJ BioPharma Cultivation will be supplying MMJIH with extracts from the marijuana plant to support its investigational new drug (IND) filings with the FDA for Multiple Sclerosis and Huntington's disease.”

Licensing / partnership

Newly added product (Yahoo Finance) - Preclinical, Huntington's Disease

Pipeline update